Compare Recursion Pharmaceuticals Inc (RXRX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Xpeng Inc - ADR — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Xpeng Inc - ADR trades at $10.45 (market cap $10.34B). The key difference: Xpeng Inc - ADR is far larger — about 5.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| RXRX | XPEV | |
|---|---|---|
Market Cap | $1.86B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $28.07 |
52-Week Low | $2.84 | $10.57 |
Enterprise Value | $1.38B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
XPeng (XPEV) trades at $10.93, down 0.18% on the day, with a bearish technical signal and negative earnings in recent quarters. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, and cash flow trends show volatility. Recent news highlights expansion into humanoid robotics, with the robotics unit raising over $900 million at a $6.3 billion valuation in August 2026.
The outlook is mixed: analyst consensus is bullish with a $19.00 price target, but execution risks in the competitive EV market and persistent losses pose challenges. Robotics diversification offers long-term potential, yet near-term profitability remains uncertain amid weak delivery forecasts and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
